High γ‐ <scp>H2AX</scp> Predicts Clinical Benefit From Platinum‐Based Chemotherapy ( <scp>mFOLFIRINOX</scp> ) at Recurrence After Pancreatic Cancer Resection
γ-H2AX overexpression in PDAC tissue is an independent negative prognostic factor. In recurrent cases, high γ-H2AX expression suggests better OS and treatment response with mFOLFIRINOX, indicating its potential as a chemosensitivity marker for personalized therapy in PDAC recurrence.
Authors
- Takashi Matsumoto (ORCID: https://orcid.org/0000-0001-6791-6441)
- Toru Takematsu (ORCID: https://orcid.org/0000-0003-4167-061X)
- Hiromitsu Hayashi (ORCID: https://orcid.org/0000-0002-1832-4287)
- Kosuke Mima (ORCID: https://orcid.org/0000-0002-4385-4984)
- Hirohisa Okabe (ORCID: https://orcid.org/0000-0003-3041-7563)
- Masaaki Iwatsuki (ORCID: https://orcid.org/0000-0002-0886-4618)
- Shinsei Yumoto
- Zhao Liu (ORCID: https://orcid.org/0000-0003-2058-1562)
- Yuki Kitano (ORCID: https://orcid.org/0000-0001-6292-8670)
- Shigeki Nakagawa
- Kosuke Kanemitsu (ORCID: https://orcid.org/0000-0001-7054-2022)
Institutions
- Kumamoto University (JP)
Publication Details
- Journal
- Journal of Hepato-Biliary-Pancreatic Sciences
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1002/jhbp.70032
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00